Full Press Release Details
Powered and protected by
Privacy
DMAC Neutral Sentiment Score: 50/100
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Key Takeaway: DiaMedica has received feedback from the FDA regarding its nonclinical program for DM199, which is aimed at addressing preeclampsia. The details of the feedback and its implications for the program have not been disclosed. This interaction with the FDA is a crucial step in the development process for DM199.